Christopher M. Adams, MD, PhD – President
Chris Adams founded Emmyon in 2012 and has served as President since its inception. He is a physician-scientist and a Professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa. His clinical practice is in internal medicine and endocrinology. His research primarily focuses on molecular mechanisms and treatment of skeletal muscle atrophy. He received his MD and PhD degrees from the University of Iowa in 1999, and then completed an internship and residency in Internal Medicine, a fellowship in Endocrinology and Metabolism, and post-doctoral training at the University of Texas Southwestern Medical Center before joining the faculty at the University of Iowa in 2006. He was elected to the American Society for Clinical Investigation in 2013.
John J. Talley, PhD – Senior Scientific Advisor
John Talley has led the medicinal chemistry program at Emmyon since 2012. He is one of the world’s most accomplished medicinal chemists and an inventor on more than 200 issued U.S. patents. He is the lead inventor of several commercial medicines including the COX-2 specific inhibitors Celebrex®, Bextra®, Dynastat®, Deramaxx® and Trocoxil®. He received the prestigious PhRMA Discoverers Award in 2002 for the discovery of Celebrex®. He is also co-inventor of the hydroxyethyl sulfonamide class of inhibitors for the treatment of HIV/AIDS, marketed under the brand names of Agenerase® , Telzir® , and Prezista®. He spent 15 years at G.D. Searle (Pharmacia/Pfizer), leading drug discovery efforts in a number of therapeutic areas, before joining Ironwood Pharmaceuticals, Inc., a public drug discovery company in Cambridge, MA. At Ironwood Pharmaceuticals (2002 – 2010), he served as VP of Drug Discovery, SVP of Drug Discovery and Distinguished Scientist.
Michael J. Welsh, MD – Senior Scientific Advisor
Mike Welsh co-founded Emmyon in 2012 and has served as a scientific advisor since its inception. He is a physician-scientist, an Investigator of the Howard Hughes Medical Institute, and a Professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa. His research is primarily focused on understanding the biology, pathogenesis and treatment of cystic fibrosis. Dr. Welsh received his MD and completed internship and residency in Internal Medicine at the University of Iowa. He trained in pulmonary medicine and research at the University of California at San Francisco and the Department of Physiology and Cell Biology at the University of Texas in Houston. He became an HHMI Investigator in 1989. He has served as President of the American Society for Clinical Investigation and the Association of American Physicians. He was elected to the Institute of Medicine (1997), the American Academy of Arts and Sciences (1998), and the National Academy of Sciences (2000).
Scott Ebert, PhD – Senior Research Scientist
Scott Ebert joined Emmyon as a Research Scientist in 2013. He received his bachelor’s degree from North Dakota State University in 2007, and then completed PhD training with Chris Adams at the University of Iowa, receiving a PhD in Molecular and Cellular Biology in 2012. Over the past seven years, Dr. Ebert has played a central role in the development of ursolic acid, tomatidine, and other small molecules that are being developed at Emmyon and he has authored ten peer-reviewed manuscripts concerning mechanisms and treatment of skeletal muscle atrophy.
Michael C. Dyle, PhD – Research Scientist
Dr. Dyle joined Emmyon as a Research Scientist in 2016. He received his bachelor’s degree from Grinnell College in 2010, and then completed PhD training with Chris Adams at the University of Iowa, receiving a PhD in Molecular Physiology and Biophysics in 2015. Dr. Dyle has authored eight peer-reviewed manuscripts concerning mechanisms and treatment of skeletal muscle atrophy and he has played a key role in the development of tomatidine and other small molecules that are being developed at Emmyon.
Hayden J. Trubitt, JD – Outside Legal Advisor
Hayden Trubitt has been outside legal advisor for Emmyon since its founding in 2012. He is a shareholder in the corporate law practice of Stradling Yocca Carlson & Rauth, P.C., San Diego, California. He received his JD, magna cum laude, in 1979 from Harvard Law School, where he was a senior editor of the Harvard Law Review. His fellow law review editors included John Roberts, now Chief Justice of the United States. Mr. Trubitt has practiced corporate law in San Diego for more than 35 years, and was one of the pioneers in representing emerging company issuers in that region.
Philip E. Hansen, PhD – Outside Patent Advisor
Dr. Hansen is outside patent advisor for Emmyon. He is a registered patent agent and a partner in the intellectual property firm of Heslin Rothenberg Farley & Mesiti P.C., Albany, New York. His background includes 16 years of experience as a research chemist in the pharmaceutical industry and 28 years as a patent agent to the prosecution of patent applications. He is registered to practice before the U.S. Patent and Trademark Office. Dr. Hansen is a graduate of Princeton University with an AB in Chemistry, and earned his PhD in Chemistry at Cornell.
Erica M. Hines, MBA, JD – Outside Patent Counsel
Ms. Hines is outside patent counsel for Emmyon. She is a registered patent attorney and an associate in the intellectual property firm of Heslin Rothenberg Farley & Mesiti P.C., Albany, New York. Ms. Hines is a graduate of Boston College, received her JD, magna cum laude, from Albany Law School, and currently serves as Chairperson of the Young Lawyers Section of the New York State Bar Association.